Evidence map›Paper›PMID 35257458›Full record

ReviewInternal medicine journal2022

Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction.

Mansi Tiwary, Tamara Y Milder, Sophie L Stocker, Richard O Day, Jerry R Greenfield

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Internal medicine journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Mansi TiwarySt Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0001-9561-052X
Tamara Y MilderSt Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Sophie L StockerSt Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-2114-587X
Richard O DaySt Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-6045-6937
Jerry R GreenfieldSt Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-0866-0973
Garvan Institute of Medical Research · AUThe University of Sydney · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global burden of chronic kidney disease (CKD) has increased significantly over the past few decades. This reflects the rising prevalence of type 2 diabetes mellitus (T2DM) and hypertension, two leading causes of CKD. Hypertension, which can also be a complication of CKD, accelerates renal disease progression and augments cardiovascular risk, especially in individuals with diabetic kidney disease. Hence, blood pressure (BP) reduction is a vital component of CKD management. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a relatively novel class of medications developed to treat T2DM by inducing glycosuria and hence, lowering glycaemia. Additionally, SGLT2 inhibitors are antihypertensive, renoprotective and cardioprotective, even in individuals without T2DM, making them effective therapeutic agents for CKD. Another therapy that has proven to be antihypertensive, renoprotective and cardioprotective is dietary sodium restriction. This review evaluates the potential combined benefits of SGLT2 inhibition and dietary sodium restriction on the BP and renal parameters of individuals with CKD.

Indexed as

Diabetes Mellitus, Type 2HypertensionRenal Insufficiency, ChronicSodium, DietarySodium-Glucose Transporter 2 InhibitorsAntihypertensive AgentsBlood GlucoseHumansHypoglycemic AgentsKidneySodiumSodium-Glucose Transporter 2Antihypertensive AgentsBlood GlucoseHypoglycemic AgentsSLC5A2 protein, humanSodiumSodium, DietarySodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitorsblood pressurechronic kidney diseasediabetic nephropathydietary sodiumSGLT2 inhibitor

Identifiers

PMID35257458
PMCPMC9796501
OpenAlexW4220751332

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.